The nanoemulsion delivery system developer raised series A funding from Haohai Biological alongside an $8m payment for the Chinese rights to its products.
Dell Technologies Capital returned for a round that took the cancer diagnostics technology developer's overall funding to $52m.
Grifols has agreed to buy the remaining 56% of antibody drug developer GigaGen having invested $35m four years ago.
Johnson & Johnson Innovation – JJDC helped the eye drop developer close a series A round that will fund development of lead asset Brimochol.
Koch Disruptive Technologies has provided $110m for the drug discovery technology startup's series B round following a $190m first close in January.
The computational pathology technology provider has added $25m to a round co-led by Johnson & Johnson Innovation – JJDC.
Novo will exit the musculoskeletal disease drug developer, should the latter complete an initial public offering on the Nasdaq Global Market.
SR One is line for an exit from the small-molecule therapy developer, which has raised $170m in venture funding in the past year.
Astellas Venture Management is among the new investors in the cancer immunotherapy developer, which was spun off by PhoreMost four years ago.
Quench Bio will wind down after its protein target proved undruggable and will return capital to investors including AbbVie Ventures.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
